Werewolf Therapeutics Presents Early Safety and Effectiveness Results from Phase 1 Study of WTX-330 in Patients with Advanced Solid Tumors or Non-Hodgkin Lymphoma.

The FDA approved Bafiertam for the treatment of relapsing forms of multiple sclerosis (MS) on April 28, 2020.

EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.

MenQuadfi, a meningococcal conjugate vaccine, is FDA approved. The FDA granted approval for MenQuadfi on April 23, 2020.

vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.

Trodelvy (sacituzumab govitecan-hziy) received accelerated approval on April 22, 2020, for the treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) in adults who have received at least two prior therapies for metastatic disease.

Jun 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Pemigatinib on April 17, 2020.

TiumBio Unveils Promising Initial Clinical Data for TU7710, Its Hemophilia Therapy Candidate, at ISTH 2024.

Tucatinib (Tukysa) is an FDA-approved medication for treating HER2-positive breast cancer, specifically in cases where the cancer is metastatic or inoperable.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

The U.S. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).